Aclaris Therapeutics, Inc. (ACRS) Stock Score, Valuation & Financial Research
Aclaris Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 18/100.
Quick answer for ACRS
Aclaris Therapeutics, Inc. currently has a Wall Street Score of 18/100. The stored market price is $5.51. Its financial score is 27/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Aclaris Therapeutics, Inc. does
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis
ACRS financial snapshot
- Wall Street Score:
- 18/100
- Current price:
- $5.51
- Market capitalization:
- $768.8M
- Revenue:
- $8.2M
- Net income:
- $-75.7M
- Free cash flow:
- $-47.2M
- Cash:
- $19.2M
- Total debt:
- $2.1M
- EPS:
- -0.58
- Financial score:
- 27/100
- Valuation score:
- 0/100
- Revenue score:
- 5/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-47.2M, showing cash burn in the current stored period.
- The balance sheet shows $19.2M of cash versus $2.1M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 27/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ACRS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.